Researchers have identified a new regulatory mechanism of the tumour-promoting protein LSD1

A recent study by scientists led by Dr Philipp Rathert from the University of Stuttgart opens up new prospects for the development of targeted cancer therapies. The researchers identified NEK6 as a previously unknown regulator of the LSD1 protein, which plays a key role in the development of various types of cancer. The research findings have now been published in the renowned journal *Communications Biology*. The Wilhelm Sander Foundation funded the project with 104,000 euros.


Colorectal cancer research: High blood pressure medication as a new treatment option

An international team of scientists led by Dr Dominic Bernkopf from Friedrich-Alexander University Erlangen-Nuremberg (FAU) has unravelled a mechanism that enables active substances originally developed to treat high blood pressure to be used specifically to combat bowel cancer. In preclinical studies, this innovative approach significantly inhibited the growth of bowel cancer. The Wilhelm Sander Foundation funded the project with 247,000 euros.


New findings: Acute myeloid leukaemia and chemotherapy cause long-term damage to the nervous system in the bone marrow

Researchers led by Tatyana Grinenko and Martin Bornhäuser from TU Dresden have developed a new method to visualise the 3D architecture of human bone marrow. They investigated changes in the bone marrow caused by acute myeloid leukaemia (AML), a fatal form of blood cancer, and discovered damage to the sympathetic nerve fibres in AML patients, which is exacerbated by chemotherapy. As the sympathetic nervous system controls blood formation, damage to it can impair the production of blood cells. A nerve-protective treatment could open up a new avenue of therapy. The project received €125,000 in funding from the Wilhelm Sander Foundation.


How a lack of oxygen protects cervical cancer cells from chemotherapy

Cervical cancer is the fourth most common malignant tumour in women worldwide. Depending on the stage of the tumour, chemotherapy plays an important role in the treatment of cervical cancer. Researchers led by Prof. Felix Hoppe-Seyler at the German Cancer Research Centre in Heidelberg (DKFZ) have now shown that a specific form of oxygen deprivation provides cervical cancer cells with particularly effective protection against chemotherapy. This increased resistance in tumour cells is due to the inhibition of a protein that plays a key role in triggering cell death during chemotherapy. The Wilhelm Sander Foundation has funded the project with €130,000.


Fatty liver and hepatocellular carcinoma: Researchers discover a protein that drives these diseases

Non-alcoholic fatty liver disease is the most common liver condition worldwide. If left untreated, it can lead to the development of hepatocellular carcinoma. Researchers led by Ralf Weiskirchen and Anastasia Asimakopoulos from the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry at RWTH Aachen University Hospital have investigated the underlying molecular mechanisms and discovered a protein that drives the development of fatty liver and hepatocellular carcinoma. These findings may lead to new therapeutic strategies for treating fatty liver disease and its associated complications. The Wilhelm Sander Foundation has funded the project with €140,000.


Office Munich

Wilhelm Sander-Stiftung
Zweigstraße 10
80336 Munich

Telephone: +49 89 544 187-0
E-Mail: info@sanst.de

Office Neustadtan der Donau

Wilhelm Sander-Stiftung
Herzog-Ludwig-Straße 17
93333 Neustadt an der Donau

Telephone: +49 9445 99199-0
E-Mail: neustadt@sanst.de

Office Leverkusen

Wilhelm Sander-Stiftung
Mülheimer Straße 76 a
51375 Leverkusen-Schlebusch

Telephone: +49 214 855 18-0
E-Mail: hv-leverkusen@sanst.de

Follow us on Linkedin


© 2026: Wilhelm Sander-Stiftung

Büro München

Wilhelm Sander-Stiftung
Zweigstraße 10
80336 München

Telefon: +49 89 544 187-0
E-Mail: info@sanst.de

Büro Neustadtan der Donau

Wilhelm Sander-Stiftung
Herzog-Ludwig-Straße 17
93333 Neustadt

Telefon: +49 9445 99199-0
E-Mail: neustadt@sanst.de

Büro Leverkusen

Wilhelm Sander-Stiftung
Mülheimer Straße 76 a
51375 Leverkusen-Schlebusch

Telefon: +49 214 855 18-0
E-Mail: hv-leverkusen@sanst.de


© 2026: Wilhelm Sander-Stiftung

Privacy Preference Center